Comparative Cost-Effectiveness Analysis of Respiratory Syncytial Virus Vaccines for Older Adults in Hong Kong

Two respiratory syncytial virus (RSV) vaccines (AREXVY(®) and ABRYSVO(®)) were recently approved for older adults in the US. This study aimed to evaluate the cost-effectiveness of AREXVY(®) and ABRYSVO(®) from the Hong Kong public healthcare provider’s perspective. A two-year decision-analytical mod...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yingcheng, Fekadu, Ginenus, You, Joyce H. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610694/
https://www.ncbi.nlm.nih.gov/pubmed/37897008
http://dx.doi.org/10.3390/vaccines11101605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610694/
https://www.ncbi.nlm.nih.gov/pubmed/37897008
http://dx.doi.org/10.3390/vaccines11101605

Ejemplares similares